Ozempic is easier to get in 2025 than it has been in years. The FDA officially declared the semaglutide shortage resolved in February 2025, ending a supply crunch that had persisted since 2022. That said, “not in shortage” doesn’t mean every patient walks out of the pharmacy with a filled prescription on the first try. Cost, insurance hurdles, and lingering spot shortages at individual pharmacies can still make the process frustrating.
The Shortage Is Officially Over
Semaglutide injection products, the active ingredient in both Ozempic and Wegovy, were on the FDA’s drug shortage list from 2022 through early 2025. Explosive demand for weight loss outpaced what Novo Nordisk could manufacture. In February 2025, the FDA confirmed with the manufacturer that current production capacity can meet both present and projected national demand, and semaglutide no longer appears on the shortage list.
Novo Nordisk is also investing heavily to stay ahead of demand. The company announced a $1.09 billion expansion of its manufacturing facility in Brazil, with a new 74,000-square-meter plant expected to begin operations in 2028. That facility will produce injectable GLP-1 medicines including semaglutide. So while the immediate crisis has passed, the company is clearly preparing for sustained high demand.
In practice, some pharmacies may still run out of specific dose strengths temporarily. If your local pharmacy doesn’t have your prescribed dose in stock, calling around to other locations or asking your pharmacist to check availability across their network often solves the problem within a few days.
Insurance Is Often the Bigger Barrier
For many people, the real difficulty isn’t finding Ozempic on a pharmacy shelf. It’s getting insurance to pay for it. Ozempic is FDA-approved specifically for type 2 diabetes, not for weight loss alone. Most insurance plans cover it for diabetes, but insurers have been tightening access through a process called prior authorization, which requires your doctor to submit paperwork justifying the prescription before the plan will approve it.
Research from the University of Pennsylvania’s Leonard Davis Institute found that insurers increased their use of prior authorization for GLP-1 drugs, and that these requirements block access even for patients who are clinically eligible. Your doctor may need to document that you’ve tried other diabetes medications first (a policy called step therapy), show specific lab results, or demonstrate that your condition meets the plan’s criteria. This process can take days to weeks, and denials aren’t uncommon on the first attempt.
If you’re hoping to use Ozempic for weight loss rather than diabetes, insurance coverage becomes much harder. Most plans don’t cover it for that purpose, since its approved indication is diabetes management. Wegovy, which contains the same active ingredient at a higher dose, is the version approved for weight management, but many insurers restrict that too.
What It Costs Without Insurance
If you’re paying out of pocket, Ozempic is expensive. Novo Nordisk offers a direct pricing program for people with type 2 diabetes who don’t have insurance: $349 per month for the 0.25 mg, 0.5 mg, or 1 mg doses, and $499 per month for the 2 mg dose. Those prices are significantly lower than the full list price, but still a substantial monthly expense.
For people who do have commercial insurance, Novo Nordisk offers a savings card that can reduce your copay. The amount it saves depends on your plan’s specific cost-sharing structure. It won’t help if your insurer hasn’t approved the prescription in the first place, though, so prior authorization still needs to clear before the savings card becomes useful.
What Your Doctor Can Do if You Can’t Get It
Doctors have developed practical workarounds from the years of supply problems. If your specific dose isn’t available, your provider may temporarily lower your dose rather than have you skip it entirely. Maintaining some level of the drug is preferable to missing doses and then needing to slowly re-titrate back up, which can take weeks and cause more side effects.
Switching to a different medication in the same class is another common strategy. Mounjaro and Zepbound (both containing tirzepatide) work through a similar mechanism and may be available when Ozempic isn’t. Your doctor can also adjust other parts of your treatment plan, adding or modifying complementary therapies to keep your blood sugar or weight management on track while you work through access issues.
Providers generally prioritize patients who need these medications for diabetes management over those using them primarily for weight loss, especially when supply is tight at a particular pharmacy.
Why Compounded Versions Are Risky
During the shortage, compounding pharmacies stepped in to produce their own versions of semaglutide. Now that the shortage is resolved, the legal landscape for these products has shifted, and the FDA has raised serious safety concerns about them.
Compounded semaglutide is not FDA-approved, meaning no one reviews these products for safety, effectiveness, or quality before they’re sold. The FDA has received 605 adverse event reports associated with compounded semaglutide as of July 2025. Many of these involved dosing errors: patients measuring incorrect amounts from vials, or healthcare professionals miscalculating doses. Some cases required hospitalization.
Other problems the FDA has flagged include products arriving warm without adequate cold packing (injectable semaglutide requires refrigeration), doses prescribed beyond what the approved drug label recommends, and products containing salt forms of semaglutide (like semaglutide sodium or semaglutide acetate) that have different chemical properties than the ingredient in approved drugs. The FDA has also found fraudulent products with false label information and has issued warnings to companies selling unapproved drugs disguised as “for research purposes.”
If someone offers you a significantly cheaper semaglutide product from a compounding pharmacy or an online source, the savings come with real risks that the brand-name version doesn’t carry.
How to Improve Your Chances
Getting Ozempic in 2025 is mostly a paperwork and cost problem rather than a supply problem. A few steps can smooth the process:
- Ask your doctor to start the prior authorization early. Don’t wait until you’re at the pharmacy to discover your plan requires approval. Many offices have staff dedicated to handling these requests.
- Check multiple pharmacies. Availability can vary from one location to another, even within the same chain. Specialty pharmacies sometimes have stock when retail locations don’t.
- Apply for the manufacturer savings card. If you have commercial insurance, it can meaningfully reduce your copay. If you’re uninsured and have type 2 diabetes, Novo Nordisk’s direct pricing program brings the cost well below list price.
- Appeal denials. If your insurer denies prior authorization, your doctor can submit additional documentation or request a peer-to-peer review. First denials are often reversed on appeal.
- Discuss alternatives with your provider. If Ozempic specifically is hard to access through your plan, a different GLP-1 medication may have better coverage or availability under your insurance.